Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAACET Study
2007-007482-21Phase 4Completed
- Sponsor
- Salford Royal NHS Foundation Trust
- Start
- Aug 2009
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agalsidase beta, lisinopril, perindopril, quinapril, ramipril and 7 more in Fabry disease (FD), sponsored by Salford Royal NHS Foundation Trust. Primary endpoints: Change in renal function and Urine protein/creatinine target attainment. Started Aug 2009; status: completed.
02
Drugs
agalsidase betalisinoprilperindoprilquinaprilramipril
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2007-007482-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007482-21.